Related Experiment Video
Updated: Jun 21, 2026
07:21
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction
Sean P Didion1, Dale A Kinzenbaw, Laura I Schrader
1Department of Internal Medicine, Division of Cardiovascular Diseases, Carver College of Medicine, University of Iowa, Iowa City, IA 52242-1081, USA.
Hypertension (Dallas, Tex. : 1979)
|July 22, 2009
Summary
Interleukin 10 (IL-10) protects blood vessels from Angiotensin II (Ang II) damage by reducing oxidative stress. IL-10 deficiency worsens Ang II-induced vascular dysfunction, highlighting IL-10
Area of Science:
- Cardiovascular Biology
- Immunology
- Vascular Medicine
Background:
- Angiotensin II (Ang II) is known to induce vascular inflammation and endothelial dysfunction.
- Interleukin 10 (IL-10) is a key anti-inflammatory cytokine with potential protective roles in the vasculature.
Purpose of the Study:
- To investigate the protective role of endogenous IL-10 against Ang II-induced vascular dysfunction.
- To determine if IL-10 modulates Ang II-mediated oxidative stress in blood vessels.
Main Methods:
- Carotid arteries from wild-type and IL-10-deficient mice were studied in vitro.
- Vascular responses to acetylcholine and superoxide levels were assessed after Ang II treatment.
- Endothelial function and blood pressure were evaluated in vivo after systemic Ang II administration.
Main Results:
- Ang II impaired acetylcholine-induced relaxation in IL-10-deficient arteries, an effect mediated by superoxide.
- Vascular superoxide levels significantly increased in IL-10-deficient mice treated with Ang II.
- Systemic Ang II caused marked endothelial dysfunction in IL-10-deficient mice, which was reversed by a superoxide scavenger.
Conclusions:
- Endogenous IL-10 limits Ang II-induced oxidative stress and vascular dysfunction.
- IL-10 exerts protective effects within the vessel wall, mitigating Ang II-mediated endothelial impairment.
- These findings suggest IL-10 as a potential therapeutic target for Ang II-related vascular diseases.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...